Anavex Life Sciences has announced promising results from a 48-week open-label extension study of
its investigational agent, ANAVEX2-73, also known as blarcamesine. The study
aimed at evaluating the efficacy and safety of blarcamesine in patients with
Parkinson disease dementia (PDD). 

The extension phase, although delayed due to the COVID-19 pandemic, demonstrated significant improvements
in the clinical symptoms of patients who continued treatment. These findings
suggest that ANAVEX2-73 has the potential to address a critical unmet need in the treatment of PDD. 

During the study, patients on blarcamesine showed marked improvements in several efficacy
endpoints, including the Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) and the Clinical Global Impression-Improvement (CGI-I)
scale. Specifically, from the open-label extension baseline to week 48, there
was a reduction of –2.25 points in the MDS-UPDRS total score and –0.7 points in
CGI-I, indicating a consistent improvement in patient conditions. 

Notably, these improvements were achieved despite an average “drug holiday” of 41
weeks due to the pandemic. This period of interrupted treatment makes the
positive outcomes even more noteworthy, underscoring the potential of
ANAVEX2-73 to provide long-term benefits. 

Anavex has emphasized the importance of these results, as they indicate the drug’s
capability to slow and potentially reverse the debilitating symptoms of
Parkinson disease. The study also highlighted that blarcamesine did not impair
sleep and had a positive effect on REM sleep behavior disorder, an encouraging
outcome for patient quality of life. 

The data from this extension study align with previously reported results from the original phase
2 trial, which also demonstrated significant clinical benefits. The consistency
of these findings enhances the credibility of ANAVEX2-73 as a promising treatment option. 

Anavex Life Sciences plans to use these insights to guide future research and development. The company is
preparing for forthcoming studies to further investigate the long-term efficacy
and safety of ANAVEX2-73 in Parkinson disease dementia. 

With these promising results, Anavex Life Sciences continues to make strides in the field,
offering hope to patients and caregivers affected by this challenging
condition. See related link for additional information. 

Like their Facebook page on https://www.facebook.com/AnavexLifeSci/